CLASS II ONGOING Drug recall · Reported 11 Nov 2026 · FDA Enforcement Report

Ciprofloxacin Tablets, USP, 750 mg recalled by Hikma Pharmaceuticals USA

Hikma Pharmaceuticals USA is recalling Ciprofloxacin Tablets, USP, 750 mg, distributed nationwide in the US. The recall was initiated on 20 Oct 2026 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot# CA083A Exp. 12/31/2026 Lot# CA084A Exp. 12/31/2026 Lot# CA085A Exp. 12/31/2026
NDC0143-9928, 0143-9927, 0143-9929
Quantity recalled20,335 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0166-2027
FDA event ID
100142
Recalling firm
Hikma Pharmaceuticals USA, Columbus, OH
Manufacturer
Hikma Pharmaceuticals USA Inc.
Classification
Class II
Status
Ongoing
Recall initiated
20 Oct 2026
FDA classified
3 Nov 2026
Reported
11 Nov 2026
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Nitrosamine Impurity
Drug class
Antibiotics

Timeline

20 Oct 2026Recall initiated by company
3 Nov 2026Classified by FDA+14 days
11 Nov 2026Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit.

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

Ciprofloxacin Tablets, USP, 750 mg, 50-count bottle, Rx Only, Manufactured by: Hikma Pharmaceuticals, P.O. Box 182400, Amman, 11118-Jordan, Distributed by: Hikma Pharmaceuticals USA Inc. Berkely Heights, NJ 07922, NDC 0143-9929-50

Where it was distributed

US Nationwide

Nationwide

Questions about this recall

Why was it recalled?

CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit.

Which lots are affected?

Lot# CA083A Exp. 12/31/2026 Lot# CA084A Exp. 12/31/2026 Lot# CA085A Exp. 12/31/2026

Where was it sold?

US Nationwide

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 17 Nov 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

1 other product · FDA event 100142
ReportedClassRecallCompanyReasonWhere
CLASS IICiprofloxacin Tablets, USP, 500 mg recalled by Hikma Pharmaceuticals USACiprofloxacinHikma Pharmaceuticals USANitrosamine ImpurityNationwide

More recalls from Hikma Pharmaceuticals USA

All 23

Other Ciprofloxacin recalls

All 21